4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > Adipogen/WY-14643/AG-CR1-3566-M250/250 mg
商品详细Adipogen/WY-14643/AG-CR1-3566-M250/250 mg
Adipogen/WY-14643/AG-CR1-3566-M250/250 mg
Adipogen/WY-14643/AG-CR1-3566-M250/250 mg
商品编号: AG-CR1-3566-M250
品牌: Adipogen Inc
市场价: ¥5600.00
美元价: 3360.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
MoreInformation
ProductDetails
SynonymsPirinixicacid;NSC310038;BRN0759945;((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)aceticacid
ProductTypeChemical
Properties
FormulaC14H14ClN3O2S
MW323.8
CAS50892-23-4
RTECSAG2915000
PurityChemicals≥98%
AppearanceOff-whitesolid.
SolubilitySolubleinethanol,DMSO,dimethylformamideorPBS(pH7.2).
InChiKeyNSHPHXHGRHSMIK-WAXGXQFOSA-N
ShippingandHandling
ShippingAMBIENT
ShortTermStorage+4°C
LongTermStorage-20°C
Use/StABIlityStableforatleast2yearsafterreceiptwhenstoredat-20°C.
Documents
MSDSDownloadPDF
ProductSpecificationSheet
DatasheetDownloadPDF
  • Potentperoxisomeproliferator-activatedreceptor(PPARα)activator[1,2,7,9].ActivatesalsoPPARγ[4,7]butnotPPARδ[8].
  • Potentanti-hypercholesterolemicagent[1].
  • Hypolipidemiccompound.Lipogenesisinducer[2,10].
  • Tumorpromoter[2,3,5,15].
  • Causesincreasedcellproliferationanddecreasedapoptosis[5].
  • Anti-inflammatory.InhibitsNF-κBtranscriptionalactivityanddecreasestheinflammatoryresponsebyreducingtheproductionofinflammatorycytokines(TNF-α,IL1β).Reducesoxidativestress[6,7,12,13].
  • Increasesfattyacidoxidation[11].
  • Directlyaffectsinsulinsignaling.Increasesglucoseuptake[12].
  • Reviews[5,11,14].
ProductReferences
  1. Apotentantihypercholesterolemicagent:(4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)aceticacid(Wy-14643):A.A.Santilli,etal.;Experientia30,1110(1974)
  2. Thehepaticeffectsofhypolipidemicdrugs(clofibrate,nafenopin,tibricacid,andWy-14,643)onhepaticperoxisomesandperoxisome-associatedenzymes:D.E.Moody&J.K.Reddy;Am.J.Pathol.90,435(1978)
  3. Peroxisomeproliferationandhepatocarcinogenesis:M.S.Rao&J.K.Reddy;Carcinogenesis 8,631(1987)
  4. Identificationofanewmemberofthesteroidhormonereceptorsuperfamilythatisactivatedbyaperoxisomeproliferatorandfattyacids: A.Schmidt, etal.;Mol.Endocrinol. 6, 1634(1992)
  5. Non-genotoxichepatocarcinogenesis:suppressionofapoptosisbyperoxisomeproliferators:R.A.Roberts;Ann.N.Y.Acad.Sci.804,588(1996)(Review)
  6. ThePPARα-leukotrieneB4pathwaytoinflammationcontrol:P.R.Devchand, etal.;Nature 384, 39 (1996)
  7. Peroxisomeproliferator-activatedreceptorsaandgareactivatedbyindomethacinandothernon-steroidalanti-inflammatorydrugs:J.M.Lehmann,etal.; J.Biol.Chem. 272, 3406(1997)
  8. Hypolipidemicdrugs,polyunsaturatedfattyacids,andeicosanoidsareligandsforperoxisomeproliferator-activatedreceptorsalphaanddelta:B.M.Forman,etal.;PNAS94,4312(1997)
  9. Activationofhumanaorticsmooth-musclecellsisinhibitedbyPPARαbutnotbyPPARγactivators:B.Staels,etal.;Nature 393, 790 (1998)
  10. Influenceofperoxisomeproliferator-activatedreceptoralphaagoNISTsontheintracellularturnoverandsecretionofapolipoprotein(Apo)B-100andApoB-48:D.Lindén,etal.;J.Biol.Chem.277,23044(2002)
  11. Peroxisomeproliferator-activatedreceptoralpha(PPARalpha)signalinginthegeneregulatorycontrolofenergymetabolisminthenormalanddiseasedheart:B.N.Finck&D.P.Kelly;J.Mol.CellCardiol.34,1249(2002)(Review)
  12. WY-14643and9-cis-retinoicacidinduceIRS-2/PI3-kinasesignallingpathwayandincreaseglucosetransportinhumanskeletalmusclecells:differentialeffectinmyotubesfromhealthysubjectsandType2diabeticpatients:K.Bouzakri,etal.;Diabetologia47,1314(2004)
  13. Oxidativestressandinflammatoryresponseevokedbytransientcerebralischemia/reperfusion:effectsofthePPAR-alphaagonistWY14643:M.Collino,etal.;FreeRADIc.Biol.Med.41,579(2006)
  14. Cardiovascularactionsoftheperoxisomeproliferator-activatedreceptor-alpha(PPARalpha)agonistWy14,643:P.Zahradka;Cardiovasc.DrugRev.25,99(2007)(Review)
  15. PPARalpha:mechanismofspeciesdifferencesandhepatocarcinogenesisofperoxisomeproliferators;F.J.Gonzalez&Y.M.Shah;Toxicology246,2(2008)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。